Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» US FDA okays Ambit Biosciences & Teva's IND for CEP-32496, a novel BRAF inhibitor
US FDA okays Ambit Biosciences & Teva's IND for CEP-32496, a novel BRAF inhibitor
US FDA okays Ambit Biosciences & Teva's IND for CEP-32496, a novel BRAF inhibitor
Submitted by
admin
on May 19, 2012 - 12:26pm
Source:
Pharmabiz
News Tags:
Ambit Biosciences
Teva Pharmaceuticals
CEP-32496
cancer
melanoma
lung cancer
thyroid cancer
colon cancer
ovarian cancer
Headline:
US FDA okays Ambit Biosciences & Teva's IND for CEP-32496, a novel BRAF inhibitor
Do Not Allow Advertisers to Use My Personal information
